Status:
COMPLETED
Efficacies of Two Bismuth Quadruple Therapies in the Second-line Treatment of H Pylori Infection
Lead Sponsor:
Ping-I (William) Hsu, M.D.
Conditions:
Helicobacter Pylori Infection
Eligibility:
All Genders
20-90 years
Phase:
NA
Brief Summary
From the profiles of antibiotic susceptibility data following eradication therapy, tetracycline, amoxicillin and levofloxacin are all good candidates of antibiotics used in the rescue treatment.
Detailed Description
The H pylori-infected adult patients with failure of standard triple therapy and H pylori-infected adult patients with failure of non-bismuth quadruple therapy are randomly assigned to either TL quadr...
Eligibility Criteria
Inclusion
- Consecutive H pylori-infected outpatients, at least 20 years of age with failure of first-line eradication treatments (standard triple, non-bismuth quadruple and bismuth quadruple therapies)
Exclusion
- previous allergic reactions to the study medications,
- history of gastrectomy,
- use of antibiotics within the previous 4 weeks,
- pregnant or lactating women,
- coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia, and malignancy).
Key Trial Info
Start Date :
July 11 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2020
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT03779087
Start Date
July 11 2018
End Date
June 30 2020
Last Update
October 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaohsiung Veterans General Hospital
Kaohsiung City, Taiwan, 813